tenosynovial giant cell tumors

Deciphera's tumor-tackling oral med achieves 40% response rate, teeing up 2024 submission
Fierce Biotech
Mon, 10/30/23 - 08:10 pm
Deciphera Pharma
clinical trials
tenosynovial giant cell tumors
vimseltinib
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
Endpoints
Mon, 08/5/19 - 11:32 am
Daiichi Sankyo
FDA
pexidartinib
Turalio
tenosynovial giant cell tumors